Tigenix S.A.U.
Quick facts
Phase 3 pipeline
- ASCs (Cx401, company code) · Dermatology / Wound Care
Cx401 is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes tissue repair and reduces inflammation in chronic wounds. - Cx601 · Gastroenterology / Immunology
Cx601 is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes tissue repair and immune modulation in the colon. - Fibrin adhesive · Surgery / Hemostasis
Fibrin adhesive acts as a biological glue that promotes hemostasis and tissue adhesion by mimicking the final stages of the coagulation cascade to form a stable fibrin clot.
Phase 2 pipeline
- ASCs · Regenerative medicine
ASCs are autologous mesenchymal stem cells used to treat various conditions. - CX501 · Muscular Dystrophy
CX501 is a gene therapy that aims to increase the production of dystrophin in patients with Duchenne muscular dystrophy.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Tigenix S.A.U.
What is Tigenix S.A.U.'s pipeline?
Tigenix S.A.U. has 3 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include ASCs (Cx401, company code), Cx601, Fibrin adhesive.
Related
- Sector hub: All tracked pharma companies